DK3458478T3 - Anti-pd-1- og anti-lag3-antistoffer til cancerbehandling - Google Patents
Anti-pd-1- og anti-lag3-antistoffer til cancerbehandling Download PDFInfo
- Publication number
- DK3458478T3 DK3458478T3 DK17726862.0T DK17726862T DK3458478T3 DK 3458478 T3 DK3458478 T3 DK 3458478T3 DK 17726862 T DK17726862 T DK 17726862T DK 3458478 T3 DK3458478 T3 DK 3458478T3
- Authority
- DK
- Denmark
- Prior art keywords
- cancer treatment
- lag3 antibodies
- lag3
- antibodies
- cancer
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title 1
- 201000011510 cancer Diseases 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/10—Plasmid DNA
- C12N2800/106—Plasmid DNA for vertebrates
- C12N2800/107—Plasmid DNA for vertebrates for mammalian
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP16170174 | 2016-05-18 | ||
PCT/EP2017/061901 WO2017198741A1 (en) | 2016-05-18 | 2017-05-17 | Anti pd-1 and anti-lag3 antibodies for cancer treatment |
Publications (1)
Publication Number | Publication Date |
---|---|
DK3458478T3 true DK3458478T3 (da) | 2021-03-22 |
Family
ID=56014918
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK17726862.0T DK3458478T3 (da) | 2016-05-18 | 2017-05-17 | Anti-pd-1- og anti-lag3-antistoffer til cancerbehandling |
Country Status (31)
Country | Link |
---|---|
US (3) | US11028169B2 (da) |
EP (2) | EP3848393A1 (da) |
JP (3) | JP6585860B2 (da) |
KR (2) | KR102419412B1 (da) |
CN (2) | CN115340608A (da) |
AR (1) | AR108516A1 (da) |
AU (1) | AU2017266298B2 (da) |
BR (1) | BR112018072986A2 (da) |
CA (1) | CA3020649A1 (da) |
CL (2) | CL2018003153A1 (da) |
CO (1) | CO2018012374A2 (da) |
CY (1) | CY1123977T1 (da) |
DK (1) | DK3458478T3 (da) |
EA (1) | EA201892616A1 (da) |
ES (1) | ES2857813T3 (da) |
HU (1) | HUE053452T2 (da) |
IL (1) | IL262892B2 (da) |
LT (1) | LT3458478T (da) |
MA (2) | MA55697A (da) |
MX (2) | MX2018014102A (da) |
MY (1) | MY193112A (da) |
PE (1) | PE20190108A1 (da) |
PH (1) | PH12018502429A1 (da) |
PL (1) | PL3458478T3 (da) |
RS (1) | RS61510B1 (da) |
SA (1) | SA518400424B1 (da) |
SG (1) | SG11201809627QA (da) |
SI (1) | SI3458478T1 (da) |
TW (2) | TW202307002A (da) |
UA (1) | UA127200C2 (da) |
WO (1) | WO2017198741A1 (da) |
Families Citing this family (88)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN114591433A (zh) | 2015-07-13 | 2022-06-07 | 西托姆克斯治疗公司 | 抗pd-1抗体、可活化抗pd-1抗体及其使用方法 |
TWI756187B (zh) | 2015-10-09 | 2022-03-01 | 美商再生元醫藥公司 | 抗lag3抗體及其用途 |
MY189018A (en) | 2015-11-18 | 2022-01-19 | Merck Sharp & Dohme | Pd1 and/or lag3 binders |
IL262892B2 (en) | 2016-05-18 | 2024-04-01 | Boehringer Ingelheim Int | Anti-PD-1 and anti-LAG3 antibodies for cancer treatment |
TWI773694B (zh) | 2016-10-11 | 2022-08-11 | 美商艾吉納斯公司 | 抗lag-3抗體及其使用方法 |
AU2017342071A1 (en) | 2016-10-13 | 2019-04-18 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd | Anti-LAG-3 antibodies and compositions |
CA3043141A1 (en) | 2016-11-18 | 2018-05-24 | Symphogen A/S | Anti-pd-1 antibodies and compositions |
EP3360898A1 (en) | 2017-02-14 | 2018-08-15 | Boehringer Ingelheim International GmbH | Bispecific anti-tnf-related apoptosis-inducing ligand receptor 2 and anti-cadherin 17 binding molecules for the treatment of cancer |
SG11201907208XA (en) | 2017-02-10 | 2019-09-27 | Regeneron Pharma | Radiolabeled anti-lag3 antibodies for immuno-pet imaging |
US11939380B2 (en) | 2017-04-05 | 2024-03-26 | Les Laboratoires Servier | Combination therapies targeting PD-1, TIM-3, and LAG-3 |
JP2020516604A (ja) * | 2017-04-05 | 2020-06-11 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 抗がん併用療法 |
JOP20190260A1 (ar) | 2017-05-02 | 2019-10-31 | Merck Sharp & Dohme | صيغ ثابتة لأجسام مضادة لمستقبل الموت المبرمج 1 (pd-1) وطرق استخدامها |
WO2018204374A1 (en) | 2017-05-02 | 2018-11-08 | Merck Sharp & Dohme Corp. | Formulations of anti-lag3 antibodies and co-formulations of anti-lag3 antibodies and anti-pd-1 antibodies |
SI3631454T1 (sl) | 2017-05-30 | 2023-12-29 | Bristol-Myers Squibb Company | Zdravljenje lag-3 pozitivnih tumorjev |
JP7301002B2 (ja) | 2017-05-30 | 2023-06-30 | ブリストル-マイヤーズ スクイブ カンパニー | 抗lag-3抗体または抗lag-3抗体および抗pd-1もしくは抗pd-l1抗体を含む組成物 |
EP4245375A3 (en) | 2017-05-30 | 2023-12-06 | Bristol-Myers Squibb Company | Compositions comprising a combination of an anti-lag-3 antibody, a pd-1 pathway inhibitor, and an immunotherapeutic agent |
US11198726B2 (en) * | 2017-06-02 | 2021-12-14 | Boerhinger Ingelheim International Gmbh | Anti-cancer combination therapy |
CN111356476B (zh) * | 2017-12-22 | 2023-03-10 | 江苏恒瑞医药股份有限公司 | Lag-3抗体药物组合物及其用途 |
CN109970856B (zh) | 2017-12-27 | 2022-08-23 | 信达生物制药(苏州)有限公司 | 抗lag-3抗体及其用途 |
CA3084518A1 (en) | 2018-01-15 | 2019-07-18 | Nanjing Legend Biotech Co., Ltd. | Single-domain antibodies and variants thereof against pd-1 |
EP3746119A4 (en) * | 2018-02-01 | 2021-11-10 | Merck Sharp & Dohme Corp. | METHODS FOR THE TREATMENT OF CANCER OR AN INFECTION USING A COMBINATION OF AN ANTI-PD -1 ANTIBODY, AN ANTI-LAG3 ANTIBODY AND AN ANTI-TIGIT ANTIBODY |
US20210085650A1 (en) * | 2018-02-22 | 2021-03-25 | The Board Of Regents Of The University Of Texas System | Combination therapy for the treatment of cancer |
FR3078536A1 (fr) * | 2018-03-05 | 2019-09-06 | Peptinov Sas | Composition vaccinale anti-pd-1 |
EP3774840A1 (en) | 2018-03-27 | 2021-02-17 | Bristol-Myers Squibb Company | Real-time monitoring of protein concentration using ultraviolet signal |
BR112020022265A2 (pt) | 2018-05-07 | 2021-02-23 | Genmab A/S | método para tratar câncer em um indivíduo, e, estojo. |
EP3569618A1 (en) | 2018-05-19 | 2019-11-20 | Boehringer Ingelheim International GmbH | Antagonizing cd73 antibody |
TW202016151A (zh) | 2018-06-09 | 2020-05-01 | 德商百靈佳殷格翰國際股份有限公司 | 針對癌症治療之多特異性結合蛋白 |
WO2019241098A1 (en) * | 2018-06-11 | 2019-12-19 | Yale University | Novel immune checkpoint inhibitors |
US20210238287A1 (en) * | 2018-07-26 | 2021-08-05 | Bristol-Myers Squibb Company | LAG-3 Combination Therapy for the Treatment of Cancer |
AU2019361124A1 (en) | 2018-10-19 | 2021-06-03 | Bristol-Myers Squibb Company | Combination therapy for melanoma |
US20210347889A1 (en) * | 2018-11-05 | 2021-11-11 | Merck Sharp & Dohme Corp. | Dosing regimen of anti-lag3 antibody and combination therapy with anti-pd-1 antibody for treating cancer |
EP3876978A4 (en) | 2018-11-07 | 2022-09-28 | Merck Sharp & Dohme Corp. | STABLE FORMULATIONS OF PROGRAMMED DEATH RECEPTOR 1 (MP-1) ANTIBODIES AND THEIR METHODS OF USE |
EP3876990A4 (en) * | 2018-11-07 | 2023-09-06 | Merck Sharp & Dohme LLC | CO-FORMULATIONS OF ANTI-LAG3 ANTIBODIES AND ANTI-PD-1 ANTIBODIES |
TW202043466A (zh) | 2019-01-25 | 2020-12-01 | 德商百靈佳殷格翰國際股份有限公司 | 編碼ccl21之重組棒狀病毒 |
WO2020172658A1 (en) | 2019-02-24 | 2020-08-27 | Bristol-Myers Squibb Company | Methods of isolating a protein |
US11578129B2 (en) * | 2019-03-29 | 2023-02-14 | Boehringer Ingelheim International Gmbh | LRP5 and PD-1 antagonist anticancer combination therapy |
BR112021021713A2 (pt) * | 2019-05-13 | 2022-04-19 | Regeneron Pharma | Método de tratamento de câncer ou inibição do crescimento de um tumor |
JP2022532930A (ja) | 2019-05-23 | 2022-07-20 | ブリストル-マイヤーズ スクイブ カンパニー | 細胞培養培地をモニターする方法 |
WO2020243563A1 (en) | 2019-05-30 | 2020-12-03 | Bristol-Myers Squibb Company | Multi-tumor gene signatures for suitability to immuno-oncology therapy |
CN114174537A (zh) | 2019-05-30 | 2022-03-11 | 百时美施贵宝公司 | 细胞定位特征和组合疗法 |
EP3976832A1 (en) | 2019-05-30 | 2022-04-06 | Bristol-Myers Squibb Company | Methods of identifying a subject suitable for an immuno-oncology (i-o) therapy |
WO2020249071A1 (en) * | 2019-06-12 | 2020-12-17 | Nanjing GenScript Biotech Co., Ltd. | Anti-pd-l1/anti-lag-3 multiple antigen binding proteins and methods of use thereof |
CN112121169B (zh) * | 2019-06-24 | 2023-10-24 | 广州再极医药科技有限公司 | 用于治疗具有高间质压力的肿瘤受试者的癌症的小分子抑制剂 |
JP6881658B2 (ja) | 2019-07-05 | 2021-06-02 | 小野薬品工業株式会社 | Pd−1/cd3二重特異性タンパク質による血液がん治療 |
WO2021024020A1 (en) | 2019-08-06 | 2021-02-11 | Astellas Pharma Inc. | Combination therapy involving antibodies against claudin 18.2 and immune checkpoint inhibitors for treatment of cancer |
JPWO2021025140A1 (da) | 2019-08-08 | 2021-02-11 | ||
CN111420049A (zh) * | 2019-08-22 | 2020-07-17 | Biocad股份公司 | 抗-pd1抗体prolgolimab的水性药物组合物及其应用 |
EP4031873A1 (en) | 2019-09-22 | 2022-07-27 | Bristol-Myers Squibb Company | Quantitative spatial profiling for lag-3 antagonist therapy |
TW202128756A (zh) | 2019-10-02 | 2021-08-01 | 德商百靈佳殷格翰國際股份有限公司 | 用於癌症治療之多重專一性結合蛋白 |
WO2021092221A1 (en) | 2019-11-06 | 2021-05-14 | Bristol-Myers Squibb Company | Methods of identifying a subject with a tumor suitable for a checkpoint inhibitor therapy |
WO2021092220A1 (en) | 2019-11-06 | 2021-05-14 | Bristol-Myers Squibb Company | Methods of identifying a subject with a tumor suitable for a checkpoint inhibitor therapy |
MX2022005474A (es) | 2019-11-08 | 2022-06-02 | Bristol Myers Squibb Co | Tratamiento de melanoma con antagonistas del gen 3 de activacion de linfocitos (lag-3). |
CN110950966B (zh) * | 2019-12-13 | 2020-12-11 | 启辰生生物科技(珠海)有限公司 | 融合蛋白、编码核酸和细胞及用途 |
US20230087600A1 (en) | 2020-02-06 | 2023-03-23 | Bristol-Myers Squibb Company | Il-10 and uses thereof |
IL298648A (en) | 2020-06-03 | 2023-01-01 | Boehringer Ingelheim Int | Recombinant rhabdovirus coding for a fc fusion protein with a cd80 extracellular site |
CN111808192B (zh) * | 2020-06-05 | 2022-02-15 | 北京天广实生物技术股份有限公司 | 结合lag3的抗体及其用途 |
CA3182579A1 (en) | 2020-07-07 | 2022-01-13 | Ugur Sahin | Therapeutic rna for hpv-positive cancer |
WO2022047189A1 (en) | 2020-08-28 | 2022-03-03 | Bristol-Myers Squibb Company | Lag-3 antagonist therapy for hepatocellular carcinoma |
EP4204453A1 (en) | 2020-08-31 | 2023-07-05 | Bristol-Myers Squibb Company | Cell localization signature and immunotherapy |
AU2021347967A1 (en) | 2020-09-24 | 2023-06-01 | Merck Sharp & Dohme Llc | Stable formulations of programmed death receptor 1 (pd-1) antibodies and hyaluronidase variants and fragments thereof and methods of use thereof |
WO2022076318A1 (en) | 2020-10-05 | 2022-04-14 | Bristol-Myers Squibb Company | Methods for concentrating proteins |
CA3196496A1 (en) | 2020-10-23 | 2022-04-28 | Laurence David TOMS | Lag-3 antagonist therapy for lung cancer |
MX2023005528A (es) | 2020-11-17 | 2023-06-23 | Seagen Inc | Metodos de tratamiento del cancer con una combinacion de tucatinib y un anticuerpo anti-pd-1/anti-pd-l1. |
WO2022120179A1 (en) | 2020-12-03 | 2022-06-09 | Bristol-Myers Squibb Company | Multi-tumor gene signatures and uses thereof |
WO2022135666A1 (en) | 2020-12-21 | 2022-06-30 | BioNTech SE | Treatment schedule for cytokine proteins |
TW202245808A (zh) | 2020-12-21 | 2022-12-01 | 德商拜恩迪克公司 | 用於治療癌症之治療性rna |
WO2022135667A1 (en) | 2020-12-21 | 2022-06-30 | BioNTech SE | Therapeutic rna for treating cancer |
AU2021416156A1 (en) | 2020-12-28 | 2023-06-22 | Bristol-Myers Squibb Company | Methods of treating tumors |
US20220233693A1 (en) | 2020-12-28 | 2022-07-28 | Bristol-Myers Squibb Company | Antibody Compositions and Methods of Use Thereof |
EP4313127A1 (en) | 2021-03-29 | 2024-02-07 | Juno Therapeutics, Inc. | Methods for dosing and treatment with a combination of a checkpoint inhibitor therapy and a car t cell therapy |
WO2022240741A1 (en) | 2021-05-12 | 2022-11-17 | Dana-Farber Cancer Institute, Inc. | Lag3 and gal3 inhibitory agents, xbp1, cs1, and cd138 peptides, and methods of use thereof |
TW202317625A (zh) | 2021-06-17 | 2023-05-01 | 德商百靈佳殷格翰國際股份有限公司 | 新穎三特異性結合分子 |
AU2022312698A1 (en) | 2021-07-13 | 2024-01-25 | BioNTech SE | Multispecific binding agents against cd40 and cd137 in combination therapy for cancer |
CA3234647A1 (en) | 2021-10-06 | 2023-04-13 | Genmab A/S | Multispecific binding agents against pd-l1 and cd137 in combination therapy |
TW202333802A (zh) | 2021-10-11 | 2023-09-01 | 德商拜恩迪克公司 | 用於肺癌之治療性rna(二) |
WO2023077090A1 (en) | 2021-10-29 | 2023-05-04 | Bristol-Myers Squibb Company | Lag-3 antagonist therapy for hematological cancer |
WO2023083439A1 (en) | 2021-11-09 | 2023-05-19 | BioNTech SE | Tlr7 agonist and combinations for cancer treatment |
WO2023147371A1 (en) | 2022-01-26 | 2023-08-03 | Bristol-Myers Squibb Company | Combination therapy for hepatocellular carcinoma |
WO2023164638A1 (en) | 2022-02-25 | 2023-08-31 | Bristol-Myers Squibb Company | Combination therapy for colorectal carcinoma |
WO2023168404A1 (en) | 2022-03-04 | 2023-09-07 | Bristol-Myers Squibb Company | Methods of treating a tumor |
WO2023170606A1 (en) | 2022-03-08 | 2023-09-14 | Alentis Therapeutics Ag | Use of anti-claudin-1 antibodies to increase t cell availability |
WO2023173011A1 (en) | 2022-03-09 | 2023-09-14 | Bristol-Myers Squibb Company | Transient expression of therapeutic proteins |
WO2023178329A1 (en) | 2022-03-18 | 2023-09-21 | Bristol-Myers Squibb Company | Methods of isolating polypeptides |
WO2023183317A2 (en) * | 2022-03-21 | 2023-09-28 | Ab Therapeutics, Inc. | Multispecific antibodies and uses thereof |
WO2023218046A1 (en) | 2022-05-12 | 2023-11-16 | Genmab A/S | Binding agents capable of binding to cd27 in combination therapy |
WO2023235847A1 (en) | 2022-06-02 | 2023-12-07 | Bristol-Myers Squibb Company | Antibody compositions and methods of use thereof |
WO2024013315A1 (en) | 2022-07-15 | 2024-01-18 | Boehringer Ingelheim International Gmbh | Binding molecules for the treatment of cancer |
CN115960834B (zh) * | 2023-03-07 | 2023-06-09 | 浙江省肿瘤医院 | 一种pd-1/ptx联合pd-1耐药模型建立的方法 |
Family Cites Families (37)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3785186T2 (de) | 1986-09-02 | 1993-07-15 | Enzon Lab Inc | Bindungsmolekuele mit einzelpolypeptidkette. |
DE3883899T3 (de) | 1987-03-18 | 1999-04-22 | Sb2 Inc | Geänderte antikörper. |
EP0368684B2 (en) | 1988-11-11 | 2004-09-29 | Medical Research Council | Cloning immunoglobulin variable domain sequences. |
GB8905669D0 (en) | 1989-03-13 | 1989-04-26 | Celltech Ltd | Modified antibodies |
US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
ES2162823T5 (es) | 1992-08-21 | 2010-08-09 | Vrije Universiteit Brussel | Inmunoglobulinas desprovistas de cadenas ligeras. |
JP3720353B2 (ja) | 1992-12-04 | 2005-11-24 | メディカル リサーチ カウンシル | 多価および多重特異性の結合タンパク質、それらの製造および使用 |
ES2138662T3 (es) | 1993-06-03 | 2000-01-16 | Therapeutic Antibodies Inc | Produccion de fragmentos de anticuerpos. |
GB9625640D0 (en) | 1996-12-10 | 1997-01-29 | Celltech Therapeutics Ltd | Biological products |
US6329516B1 (en) | 1997-04-28 | 2001-12-11 | Fmc Corporation | Lepidopteran GABA-gated chloride channels |
CA2288994C (en) | 1997-04-30 | 2011-07-05 | Enzon, Inc. | Polyalkylene oxide-modified single chain polypeptides |
WO2001079442A2 (en) | 2000-04-12 | 2001-10-25 | Human Genome Sciences, Inc. | Albumin fusion proteins |
IL156955A0 (en) | 2001-01-17 | 2004-02-08 | Genecraft Inc | Binding domain-immunoglobulin fusion proteins |
EP1456410A2 (en) | 2001-12-11 | 2004-09-15 | AlgoNomics N.V. | Method for displaying loops from immunoglobulin domains in different contexts |
DK1517921T3 (da) | 2002-06-28 | 2006-10-09 | Domantis Ltd | Immunglobulin-enkeltvariable antigen-bindende domæner og dobbeltspecifikke konstruktioner deraf |
EP2316852B1 (en) | 2002-11-08 | 2014-03-05 | Ablynx N.V. | Stabilized single domain antibodies |
WO2004056875A1 (en) | 2002-12-23 | 2004-07-08 | Wyeth | Antibodies against pd-1 and uses therefor |
AU2004220325B2 (en) | 2003-06-30 | 2011-05-12 | Domantis Limited | Polypeptides |
AR072999A1 (es) * | 2008-08-11 | 2010-10-06 | Medarex Inc | Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos |
TW201134488A (en) | 2010-03-11 | 2011-10-16 | Ucb Pharma Sa | PD-1 antibodies |
US9290564B2 (en) * | 2012-05-24 | 2016-03-22 | Mountgate Group Limited | Compositions and methods related to the prevention and treatment of rabies infection |
AR091649A1 (es) * | 2012-07-02 | 2015-02-18 | Bristol Myers Squibb Co | Optimizacion de anticuerpos que se fijan al gen de activacion de linfocitos 3 (lag-3) y sus usos |
US10280221B2 (en) * | 2013-03-15 | 2019-05-07 | Glaxosmithkline Intellectual Property Development Limited | Anti-LAG-3 binding proteins |
MX2015015037A (es) * | 2013-05-02 | 2016-07-08 | Anaptysbio Inc | Anticuerpos dirigidos contra la proteina muerte programada-1 (pd-1). |
AU2014323523B2 (en) * | 2013-09-20 | 2020-02-20 | Bristol-Myers Squibb Company | Combination of anti-LAG-3 antibodies and anti-PD-1 antibodies to treat tumors |
KR102395820B1 (ko) | 2013-11-05 | 2022-05-09 | 버베리안 노딕 에이/에스 | 종양 항원을 발현하는 폭스바이러스 및 면역 관문 저해제의 길항제 및/또는 효현제를 구비하는 암을 치료하기 위한 복합제 치료제 |
US10344090B2 (en) * | 2013-12-12 | 2019-07-09 | Shanghai Hangrui Pharmaceutical Co., Ltd. | PD-1 antibody, antigen-binding fragment thereof, and medical application thereof |
BR112016018408A2 (pt) * | 2014-03-14 | 2017-12-26 | Immutep Sas | moléculas de anticorpo à lag-3 e usos das mesmas |
TW201609812A (zh) * | 2014-07-31 | 2016-03-16 | 安美基研究(慕尼黑)公司 | 最佳化之跨物種特異性雙特異性單鏈抗體構築體 |
JO3663B1 (ar) * | 2014-08-19 | 2020-08-27 | Merck Sharp & Dohme | الأجسام المضادة لمضاد lag3 وأجزاء ربط الأنتيجين |
MA41044A (fr) | 2014-10-08 | 2017-08-15 | Novartis Ag | Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer |
SG11201702401RA (en) | 2014-10-14 | 2017-04-27 | Novartis Ag | Antibody molecules to pd-l1 and uses thereof |
TWI595006B (zh) | 2014-12-09 | 2017-08-11 | 禮納特神經系統科學公司 | 抗pd-1抗體類和使用彼等之方法 |
RS60753B1 (sr) | 2015-04-17 | 2020-10-30 | Bristol Myers Squibb Co | Kompozicije koje sadrže kombinaciju ipilimumaba i nivolumaba |
TWI773646B (zh) | 2015-06-08 | 2022-08-11 | 美商宏觀基因股份有限公司 | 結合lag-3的分子和其使用方法 |
TWI756187B (zh) | 2015-10-09 | 2022-03-01 | 美商再生元醫藥公司 | 抗lag3抗體及其用途 |
IL262892B2 (en) | 2016-05-18 | 2024-04-01 | Boehringer Ingelheim Int | Anti-PD-1 and anti-LAG3 antibodies for cancer treatment |
-
2017
- 2017-05-17 IL IL262892A patent/IL262892B2/en unknown
- 2017-05-17 TW TW111115384A patent/TW202307002A/zh unknown
- 2017-05-17 HU HUE17726862A patent/HUE053452T2/hu unknown
- 2017-05-17 UA UAA201812215A patent/UA127200C2/uk unknown
- 2017-05-17 AU AU2017266298A patent/AU2017266298B2/en active Active
- 2017-05-17 MX MX2018014102A patent/MX2018014102A/es unknown
- 2017-05-17 BR BR112018072986-8A patent/BR112018072986A2/pt unknown
- 2017-05-17 KR KR1020187033938A patent/KR102419412B1/ko active IP Right Grant
- 2017-05-17 SI SI201730636T patent/SI3458478T1/sl unknown
- 2017-05-17 DK DK17726862.0T patent/DK3458478T3/da active
- 2017-05-17 LT LTEP17726862.0T patent/LT3458478T/lt unknown
- 2017-05-17 EP EP20216343.2A patent/EP3848393A1/en active Pending
- 2017-05-17 JP JP2018555176A patent/JP6585860B2/ja active Active
- 2017-05-17 EA EA201892616A patent/EA201892616A1/ru unknown
- 2017-05-17 EP EP17726862.0A patent/EP3458478B1/en active Active
- 2017-05-17 PE PE2018002814A patent/PE20190108A1/es unknown
- 2017-05-17 WO PCT/EP2017/061901 patent/WO2017198741A1/en active Application Filing
- 2017-05-17 CA CA3020649A patent/CA3020649A1/en active Pending
- 2017-05-17 KR KR1020227023184A patent/KR20220103806A/ko not_active Application Discontinuation
- 2017-05-17 TW TW106116226A patent/TWI762484B/zh active
- 2017-05-17 CN CN202210993045.8A patent/CN115340608A/zh active Pending
- 2017-05-17 RS RS20210218A patent/RS61510B1/sr unknown
- 2017-05-17 MY MYPI2018001836A patent/MY193112A/en unknown
- 2017-05-17 ES ES17726862T patent/ES2857813T3/es active Active
- 2017-05-17 CN CN201780030891.7A patent/CN109415439B/zh active Active
- 2017-05-17 MA MA055697A patent/MA55697A/fr unknown
- 2017-05-17 AR ARP170101335A patent/AR108516A1/es unknown
- 2017-05-17 MA MA45029A patent/MA45029B1/fr unknown
- 2017-05-17 PL PL17726862T patent/PL3458478T3/pl unknown
- 2017-05-17 SG SG11201809627QA patent/SG11201809627QA/en unknown
- 2017-05-18 US US15/598,356 patent/US11028169B2/en active Active
-
2018
- 2018-10-22 JP JP2018198362A patent/JP6585801B2/ja active Active
- 2018-11-07 CL CL2018003153A patent/CL2018003153A1/es unknown
- 2018-11-13 SA SA518400424A patent/SA518400424B1/ar unknown
- 2018-11-16 CO CONC2018/0012374A patent/CO2018012374A2/es unknown
- 2018-11-16 MX MX2022008184A patent/MX2022008184A/es unknown
- 2018-11-19 PH PH12018502429A patent/PH12018502429A1/en unknown
-
2019
- 2019-09-05 JP JP2019161854A patent/JP2020007340A/ja active Pending
-
2020
- 2020-05-11 US US16/871,382 patent/US11795219B2/en active Active
-
2021
- 2021-03-22 CY CY20211100246T patent/CY1123977T1/el unknown
- 2021-08-10 CL CL2021002094A patent/CL2021002094A1/es unknown
-
2023
- 2023-09-01 US US18/459,590 patent/US20240124581A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK3458478T3 (da) | Anti-pd-1- og anti-lag3-antistoffer til cancerbehandling | |
ZA201902265B (en) | Anti-pd-1 antibodies and their uses | |
DK3455259T3 (da) | Kombination af anti-PD-1-antistoffer og stråling til cancerbehandling | |
IL267804A (en) | Methods for treating cancer with anti-pd-1 antibodies | |
HK1254880A1 (zh) | 抗pd-1抗體及其應用 | |
DK3394103T3 (da) | Kombination af anti-PD-1-antistoffer og bispecifikke anti-CD20-/anti-CD3-antistoffer til cancerbehandling | |
CL2018000281A1 (es) | Anticuerpos monoclonales contra bcma | |
HK1245134A1 (zh) | 用抗lap單克隆抗體治療癌症 | |
DK3303394T3 (da) | Anti-ctla-4-antistoffer og fremgangsmåder til anvendelse deraf | |
EP3377102C0 (en) | ANTI-PD-1 ANTIBODIES AND THEIR THERAPEUTIC USES | |
DK3616720T3 (da) | Farmaceutisk sammensætning til cancerbehandling | |
DK3508502T3 (da) | Kombination af anti-lag-3-antistoffer og anti-pd-1-antistoffer til behandling af tumorer | |
DK3368572T3 (da) | Anti-pd-1-antistoffer og -sammensætninger | |
DK3280441T3 (da) | Anti-sortilin-antistoffer og fremgangsmåder til anvendelse deraf | |
DK3189082T3 (da) | Anti-pd-l1-konjugater til behandling af tumorer | |
DK3230319T3 (da) | Anti-PD-1-antistoffer og fremgangsmåder til anvendelse deraf | |
DK3594238T3 (da) | Antistofsammensætninger til tumorbehandling | |
DK3504242T3 (da) | Anti-ox40-antistoffer og anvendelse deraf | |
DK3191135T3 (da) | Anti-HER2-antistoffer og immunokonjugater | |
DK3126394T3 (da) | Anti-OX40-antistoffer og fremgangsmåder til anvendelse | |
DK3307322T3 (da) | Humaniserede anti-cd40-antistoffer og anvendelser deraf | |
DK3221359T3 (da) | Fremgangsmåder til tumorbehandling ved anvendelse af CD3XCD20-bispecifikt antistof | |
BR112017001385A2 (pt) | anticorpos anti-pd-1 | |
DK3142751T3 (da) | Anti-B7-H1- og anti-CTLA-4-antistoffer til behandling af ikke-småcellet lungecancer | |
DK3166976T3 (da) | Anti-pd-l1-kombinationer til behandling af tumorer |